Journal
EXPERT OPINION ON DRUG DELIVERY
Volume 15, Issue 7, Pages 703-716Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/17425247.2018.1497607
Keywords
Nanogels; stimuli-sensitive; drug delivery; tumor microenvironment; anticancer drug; cancer therapy
Categories
Funding
- National Key Research and Development Program of China [2017YFD0401301, 2017YFD0400203, 2017YFD0400402]
- National Natural Science Foundation of China (NSFC) [51703244, 81600178]
- Natural Science Foundation of Jiangsu Province [BK20170730]
- Fundamental Research Funds for the Central Universities [2632017ZD01]
- Jiangsu Specially-Appointed Professors Program
Ask authors/readers for more resources
Introduction: Bioresponsive nanogels with a crosslinked three-dimensional structure and an aqueous environment that undergo physical or chemical changes including swelling and dissociation in response to biological signals such as mild acidity, hyperthermia, enzymes, reducing agents, reactive oxygen species (ROS), and adenosine-5'-triphosphate (ATP) present in tumor microenvironments or inside cancer cells have emerged as an appealing platform for targeted drug delivery and cancer therapy. Areas covered: This review highlights recent designs and development of bioresponsive nanogels for facile loading and triggered release of chemotherapeutics and biotherapeutics. The in vitro and in vivo antitumor performances of drug-loaded nanogels are discussed. Expert opinion: Bioresponsive nanogels with an excellent stability and safety profile as well as fast response to biological signals are unique systems that mediate efficient and site-specific delivery of anticancer drugs, in particular macromolecular drugs like proteins, siRNA and DNA, leading to significantly enhanced tumor therapy compared with the non-responsive counterparts. Future research has to be directed to the development of simple, tumor-targeted and bioresponsive multifunctional nanogels, which can be either constructed from natural polymers with intrinsic targeting ability or functionalized with targeting ligands. We anticipate that rationally designed nanotherapeutics based on bioresponsive nanogels will become available for future clinical cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available